Article thumbnail

Pharmacotherapy and the risk for community-acquired pneumonia

By Jen-Tzer Gau, Utkarsh Acharya, Salman Khan, Victor Heh, Lona Mody and Tzu-Cheg Kao
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2909244
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). Association between proton pump inhibitors and respiratory infections: a systematic review and metaanalysis of clinical trials.
  2. (1999). BolĂ­bar I: Proportion of communityacquired pneumonia cases attributable to tobacco smoking. Chest
  3. (1997). Breiman RF: Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The community-based pneumonia incidence study group. Arch Intern Med
  4. (1999). CA: Risk factors for communityacquired pneumonia in adults: a population-based case-control study. Eur Respir J
  5. (1996). Communityacquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med
  6. (2000). DL: Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med
  7. (2000). DL: Risk factors for communityacquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. Respir Med
  8. (2008). E: Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA
  9. (2008). Egberts AC: Antipsychotic drug use and risk of pneumonia in elderly people.
  10. (2009). ER: Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA
  11. (2004). Esophageal dysfunction on psychotropic medication. A case report and literature review. Pharmacopsychiatry
  12. (1993). Factors of importance for the long term prognosis after hospital treated pneumonia. Thorax
  13. (2000). Fawzi WW: A prospective study of age and lifestyle factors in relation to communityacquired pneumonia in US men and women. Arch Intern Med
  14. (2008). Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax
  15. (2004). JB: Risk of community-acquired pneumonia and use of gastric acidsuppressive drugs. JAMA
  16. (2006). KJ: Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest
  17. (2004). LA: The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis
  18. (2007). Lasserson TJ: Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev
  19. (1988). LJ: Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States,
  20. (2009). Loke YK: Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med
  21. (2008). Low levels of serum cholesterol and albumin and the risk of community-acquired pneumonia in young soldiers. Int J Tuberc Lung Dis
  22. (2009). Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based casecontrol study. Pharmacoepidemiol Drug Saf
  23. (2008). Shackell BS: Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir Res
  24. (2008). Statistics: The latest: Trends in pneumonia and influenza morbidity and mortality.
  25. (2007). Suissa S: Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med
  26. (2009). Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther
  27. (2009). TC: Uses of proton pump inhibitors and serum potassium levels. Pharmacoepidemiol Drug Saf
  28. (2007). TORCH investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
  29. (2009). Use of proton pump inhibitors and the risk of community-acquired Additional file 1 Appendix Table. Discharge Diagnoses of Study Patients Based on the Use of Proton-Pump Inhibitors (PPI) Prior to Admission.
  30. (2007). Vogelmeier C: Impact of Salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  31. (1989). White L: Prospective study of pneumonia hospitalizations and mortality of U.S. older people: the role of chronic conditions, health behaviors, and nutritional status. Public Health Rep
  32. (2008). Yang YX: Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med